BMJ  2006;332 (11 February), doi:10.1136/bmj.332.7537.0

Fondaparinux reduces thromboembolism in elderly medical patients

Fondaparinux, a selective factor Xa inhibitor, is effective and safe for preventing venous thromboembolism in acutely ill, medical inpatients at moderate risk. In a double blind, randomised, placebo controlled trial, Cohen and colleagues (p 325) allocated more than 800 bedridden medical patients aged 60 or older to either 2.5 mg fondaparinux or placebo given subcutaneously daily for 6-14 days. Drug treatment reduced patients' relative risk of venous thromboembolism by 47% at no increased risk of major bleeds.

Credit: CHRIS PRIEST/SPL

 

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    What's this?

Relevant Article

Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

Alexander T Cohen, Bruce L Davidson, Alexander S Gallus, Michael R Lassen, Martin H Prins, Witold Tomkowski, Alexander G G Turpie, Jan F M Egberts, Anthonie W A Lensing ARTEMIS Investigators
BMJ 2006 332: 325-329. [Abstract] [Full Text] [PDF]

Online poll

Find out more>>